{
    "patient": {
        "Name": "Tanner Harris",
        "DateOfBirth": "1988-04-26",
        "Sex": "Female",
        "Diagnosis": "Chronic lymphocytic leukemia (CLL)",
        "BodyPart": "Leukemia",
        "Physician": "Dr. Kimberly Lee",
        "TreatingInstitution": "Austin and Sons"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Leukemia",
            "CollectedDate": "2023-11-07",
            "ReceivedDate": "2023-11-07",
            "TumorPercentage": "39%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-11-09",
            "ReceivedDate": "2023-11-10"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "FBXW7",
                "DNA Alteration": "c.1394G>A",
                "GeneMutation": "p.R465H Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "25.84%"
            },
            {
                "Gene": "B2M",
                "DNA Alteration": "c.2T>G",
                "GeneMutation": "p.M1R Spliceregionvariant-LOF",
                "VariantAlleleFraction": "7.14%"
            },
            {
                "Gene": "NOTCH1",
                "DNA Alteration": "c.7398_7399insGG",
                "GeneMutation": "p.S2467Pfs*7 Frameshift-LOF",
                "VariantAlleleFraction": "15.36%"
            },
            {
                "Gene": "PHF6",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R225X Nonsense-LOF",
                "VariantAlleleFraction": "13.59%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "PTEN",
                "DNA Alteration": "c.389G>T",
                "GeneMutation": "p.R130L Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "2.92%"
            },
            {
                "Gene": "NCSTN",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R130L Nonsense-LOF",
                "VariantAlleleFraction": "14.44%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "SDHD",
            "SF3B1",
            "PRKCA"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "15 m/Mb",
            "Tmbpercentile": "77%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Stable"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "IKZF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.N159Y Frameshift-GOF",
                "VariantAlleleFraction": "6.53%"
            },
            {
                "Gene": "JAK2",
                "DNA Alteration": "c.2047A>G",
                "GeneMutation": "p.G996R Stopgain-LOF",
                "VariantAlleleFraction": "9.92%"
            },
            {
                "Gene": "FGFR4",
                "DNA Alteration": "c.1162G>A",
                "GeneMutation": "p.G388R Nonsense-GOF",
                "VariantAlleleFraction": "11.06%"
            },
            {
                "Gene": "PHF6",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R225X Frameshift-GOF",
                "VariantAlleleFraction": "3.28%"
            },
            {
                "Gene": "CCND3",
                "DNA Alteration": "c.766_776del11",
                "GeneMutation": "p.R256fs*64 Frameshift-LOF",
                "VariantAlleleFraction": "3.82%"
            },
            {
                "Gene": "PTEN",
                "DNA Alteration": "c.389G>C",
                "GeneMutation": "p.R130P Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "7.65%"
            },
            {
                "Gene": "PIK3CA",
                "DNA Alteration": "c.1634A>T",
                "GeneMutation": "p.E545V Frameshift-GOF",
                "VariantAlleleFraction": "3.3%"
            },
            {
                "Gene": "FOXL2",
                "DNA Alteration": "c.402C>G",
                "GeneMutation": "p.C134W Frameshift-GOF",
                "VariantAlleleFraction": "4.96%"
            },
            {
                "Gene": "PIK3CA",
                "DNA Alteration": "c.3139C>T",
                "GeneMutation": "p.E545K Spliceregionvariant-LOF",
                "VariantAlleleFraction": "8.81%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "BRAF",
        "KRAS"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "FBXW7",
                "DNA Alteration": "c.1394G>A",
                "GeneMutation": "p.R465H Missensevariant(exon2)-GOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "25.84%"
            },
            {
                "Gene": "B2M",
                "DNA Alteration": "c.2T>G",
                "GeneMutation": "p.M1R Spliceregionvariant-LOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "7.14%"
            },
            {
                "Gene": "NOTCH1",
                "DNA Alteration": "c.7398_7399insGG",
                "GeneMutation": "p.S2467Pfs*7 Frameshift-LOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "15.36%"
            },
            {
                "Gene": "PHF6",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R225X Nonsense-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "13.59%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "PTEN",
                "DNA Alteration": "c.389G>T",
                "GeneMutation": "p.R130L Missensevariant(exon2)-GOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "2.92%"
            },
            {
                "Gene": "NCSTN",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R130L Nonsense-LOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "14.44%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-11-06"
    },
    "other": {
        "ReportId": "3950",
        "ReportDate": "2023-11-13",
        "SignedBy": "Kimberly Lee",
        "Supervisor": "Dr. Carl Perez"
    }
}